US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
CH660375A5
(it)
|
1983-02-08 |
1987-04-15 |
Sclavo Spa |
Procedimento per la produzione di proteine correlate alla tossina difterica.
|
US4708871A
(en)
|
1983-03-08 |
1987-11-24 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
GB8424757D0
(en)
|
1984-10-01 |
1984-11-07 |
Pasteur Institut |
Retroviral vector
|
SE8405493D0
(sv)
|
1984-11-01 |
1984-11-01 |
Bror Morein |
Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
|
FR2573436B1
(fr)
|
1984-11-20 |
1989-02-17 |
Pasteur Institut |
Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
US4666829A
(en)
|
1985-05-15 |
1987-05-19 |
University Of California |
Polypeptide marker for Alzheimer's disease and its use for diagnosis
|
WO1987001130A1
(en)
|
1985-08-15 |
1987-02-26 |
Stauffer Chemical Company |
Tryptophan producing microorganism
|
US5078996A
(en)
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
AU606320B2
(en)
|
1985-11-01 |
1991-02-07 |
International Genetic Engineering, Inc. |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
US5514581A
(en)
|
1986-11-04 |
1996-05-07 |
Protein Polymer Technologies, Inc. |
Functional recombinantly prepared synthetic protein polymer
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
JPH01125328A
(ja)
|
1987-07-30 |
1989-05-17 |
Centro Natl De Biopreparados |
髄膜炎菌ワクチン
|
JPH01144977A
(ja)
|
1987-11-30 |
1989-06-07 |
Agency Of Ind Science & Technol |
新規組換えプラスミドpTPGIF2
|
CA1315719C
(en)
|
1988-02-05 |
1993-04-06 |
Arthur Bank |
Retroviral packaging cell lines and processes of using same
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
WO1990002806A1
(en)
|
1988-09-01 |
1990-03-22 |
Whitehead Institute For Biomedical Research |
Recombinant retroviruses with amphotropic and ecotropic host ranges
|
US7118757B1
(en)
|
1988-12-19 |
2006-10-10 |
Wyeth Holdings Corporation |
Meningococcal class 1 outer-membrane protein vaccine
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
ES2150450T3
(es)
|
1989-03-09 |
2000-12-01 |
American Cyanamid Co |
Procedimiento para el aislamiento de la proteina e de haemophilus influenzae.
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
GB8910570D0
(en)
|
1989-05-08 |
1989-06-21 |
Wellcome Found |
Acellular vaccine
|
CA2017507C
(en)
|
1989-05-25 |
1996-11-12 |
Gary Van Nest |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
CA2039921A1
(en)
|
1990-04-16 |
1991-10-17 |
Xandra O. Breakefield |
Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991018088A1
(en)
|
1990-05-23 |
1991-11-28 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
Adeno-associated virus (aav)-based eucaryotic vectors
|
IE912559A1
(en)
|
1990-07-19 |
1992-01-29 |
Merck & Co Inc |
The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
|
BR9106879A
(pt)
|
1990-09-25 |
1993-07-20 |
Cantab Pharma Res |
Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
IL101715A
(en)
|
1991-05-02 |
2005-06-19 |
Amgen Inc |
Recombinant dna-derived cholera toxin subunit analogs
|
EP0625052A4
(en)
|
1991-10-21 |
1995-07-19 |
Medimmune Inc |
SECRETION SIGNAL OF LIPOPROTEIN-ENCODING DNA CONTAINING BACTERIAL EXPRESSION VECTOR.
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
IT1253009B
(it)
|
1991-12-31 |
1995-07-10 |
Sclavo Ricerca S R L |
Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
|
WO1993015115A1
(en)
|
1992-01-24 |
1993-08-05 |
Cornell Research Foundation, Inc. |
E. coli dna polymerase iii holoenzyme and subunits
|
EP0911413A3
(en)
|
1992-12-03 |
2000-11-15 |
Genzyme Corporation |
Minimal adenovirus-based gene therapy vector
|
EP0616034B1
(en)
|
1993-03-05 |
2004-10-20 |
Wyeth Holdings Corporation |
Plasmid for production of CRM protein and diphtheria toxin
|
JPH08507784A
(ja)
|
1993-03-19 |
1996-08-20 |
キャンタブ ファーマシューティカルズ リサーチ リミティド |
ウイルス・ワクチン
|
DK0624376T3
(da)
|
1993-05-13 |
2000-07-24 |
American Cyanamid Co |
Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
AU7264694A
(en)
|
1993-07-13 |
1995-02-13 |
Rhone-Poulenc Rorer S.A. |
Defective adenovirus vectors and use thereof in gene therapy
|
EP0711354A1
(en)
|
1993-07-30 |
1996-05-15 |
University Of Medicine & Dentistry Of New Jersey |
Efficient gene transfer into primary lymphocytes
|
FR2708622B1
(fr)
|
1993-08-02 |
1997-04-18 |
Raymond Hamers |
Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
|
US5550213A
(en)
|
1993-12-27 |
1996-08-27 |
Rutgers, The State University Of New Jersey |
Inhibitors of urokinase plasminogen activator
|
FR2714830B1
(fr)
|
1994-01-10 |
1996-03-22 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
FR2715847B1
(fr)
|
1994-02-08 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
FR2716459B1
(fr)
|
1994-02-22 |
1996-05-10 |
Univ Paris Curie |
Système hôte-vecteur utilisable en thérapie génique.
|
AU2194895A
(en)
|
1994-03-25 |
1995-10-17 |
Uab Research Foundation, The |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
CA2187818A1
(en)
|
1994-04-15 |
1995-10-26 |
Robert W. Overell |
Gene delivery fusion proteins
|
US5571515A
(en)
|
1994-04-18 |
1996-11-05 |
The Wistar Institute Of Anatomy & Biology |
Compositions and methods for use of IL-12 as an adjuvant
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US5565204A
(en)
|
1994-08-24 |
1996-10-15 |
American Cyanamid Company |
Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
GB9422096D0
(en)
|
1994-11-02 |
1994-12-21 |
Biocine Spa |
Combined meningitis vaccine
|
FR2727679B1
(fr)
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
BE1008978A5
(fr)
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
IL117483A
(en)
|
1995-03-17 |
2008-03-20 |
Bernard Brodeur |
MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
|
US5820870A
(en)
|
1995-03-22 |
1998-10-13 |
Merck & Co., Inc. |
Recombinant human papillomavirus type 18 vaccine
|
AU6043396A
(en)
|
1995-06-05 |
1996-12-24 |
University Of Alabama At Birmingham Research Foundation, The |
Composition and methods for creating syngeneic recombinant v irus-producing cells
|
CA2704354A1
(en)
|
1995-06-07 |
1996-12-19 |
Connaught Laboratories, Inc. |
Expression of lipoproteins
|
FR2741358B1
(fr)
|
1995-11-17 |
1998-01-02 |
Centre Nat Rech Scient |
Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
|
US5846547A
(en)
|
1996-01-22 |
1998-12-08 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
US6355255B1
(en)
|
1998-12-07 |
2002-03-12 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
WO1998008543A1
(en)
|
1996-08-27 |
1998-03-05 |
Chiron Corporation |
Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
|
DE69725739T2
(de)
|
1996-08-27 |
2004-08-05 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
|
GB9622159D0
(en)
|
1996-10-24 |
1996-12-18 |
Solvay Sociutu Anonyme |
Polyanionic polymers as adjuvants for mucosal immunization
|
US6472518B1
(en)
|
1996-10-24 |
2002-10-29 |
Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services |
Invasion associated genes from Neisseria meningitidis serogroup B
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
PL337617A1
(en)
|
1997-06-30 |
2000-08-28 |
Rhone Poulenc Rorer Sa |
Apparatus for performing optimised in vivo electrotransfer of vectorial nucleic acids into tissues
|
DE69826124T3
(de)
|
1997-06-30 |
2007-10-11 |
Institut Gustave Roussy |
Verabreichung der nukleinsäure in den quergestreiften muskel
|
HUP0004728A3
(en)
|
1997-06-30 |
2003-08-28 |
Centre Nat Rech Scient |
Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
|
ATE505478T1
(de)
|
1997-08-27 |
2011-04-15 |
Novartis Vaccines & Diagnostic |
Molekular-mimetika von meningokokkalen b epitopen
|
EP1029052B1
(en)
|
1997-11-06 |
2010-08-04 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisserial antigens
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
NZ525674A
(en)
|
1998-02-03 |
2005-01-28 |
Ct Disease Contr & Prevention |
Recombinant lipidated PsaA protein, methods of preparation and use
|
GB9806456D0
(en)
|
1998-03-25 |
1998-05-27 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9808734D0
(en)
|
1998-04-23 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
GB9808932D0
(en)
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
ES2294629T3
(es)
|
1998-05-01 |
2008-04-01 |
Novartis Vaccines And Diagnostics, Inc. |
Antigenos de neisseria y composiciones.
|
NZ508771A
(en)
|
1998-05-29 |
2003-08-29 |
Chiron Corp |
Neisseria meningitidis vaccine comprising NmC oligosaccharides, NmB outer membrane proteins, and a carrier
|
DE69937571T2
(de)
|
1998-09-30 |
2008-09-04 |
The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences |
Mutiertes cholera holotoxin als hilfsmittel
|
EP1198245B1
(en)
|
1998-09-30 |
2004-08-25 |
Walter Reed Army Institute of Research |
Use of purified invaplex from gram negative bacteria as a vaccine
|
EP1559795A3
(en)
|
1998-10-09 |
2005-11-09 |
Chiron Corporation |
Neisseria genomic sequences and methods of their use
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6281337B1
(en)
|
1998-11-12 |
2001-08-28 |
Schering Corporation |
Methods for conversion of protein isoforms
|
WO2000042192A1
(en)
|
1999-01-15 |
2000-07-20 |
Smithkline Beecham Biologicals S.A. |
Neisseria meningitidis polypeptide basb052
|
CA2360658A1
(en)
|
1999-01-22 |
2000-07-27 |
Smithkline Beecham Biologicals S.A. |
Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
|
GB9902084D0
(en)
|
1999-01-29 |
1999-03-24 |
Smithkline Beecham Biolog |
Novel compounds
|
KR20010093290A
(ko)
|
1999-02-05 |
2001-10-27 |
폴락 돈나 엘. |
사람 파필로마바이러스 백신 제제
|
WO2000050075A2
(en)
|
1999-02-26 |
2000-08-31 |
Chiron S.P.A. |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
|
US6245568B1
(en)
|
1999-03-26 |
2001-06-12 |
Merck & Co., Inc. |
Human papilloma virus vaccine with disassembled and reassembled virus-like particles
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
ES2397918T3
(es)
|
1999-04-30 |
2013-03-12 |
Novartis Vaccines And Diagnostics S.R.L. |
Antígenos Neisseriales conservados
|
AU780308B2
(en)
|
1999-04-30 |
2005-03-17 |
J. Craig Venter Institute, Inc. |
Neisseria genomic sequences and methods of their use
|
EP1860191A3
(en)
|
1999-05-19 |
2008-02-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Combination neisserial compositions
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
ES2564463T3
(es)
|
1999-10-29 |
2016-03-22 |
Glaxosmithkline Biologicals S.A. |
Péptidos antigénicos de Neisseriales
|
GB9928196D0
(en)
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
AU1875301A
(en)
|
1999-11-29 |
2001-06-04 |
Chiron S.P.A. |
85kda neisserial antigen
|
ATE400296T1
(de)
|
1999-12-02 |
2008-07-15 |
Novartis Vaccines & Diagnostic |
Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
|
PT2289545T
(pt)
|
2000-01-17 |
2016-09-06 |
Glaxosmithkline Biologicals Sa |
Vacina de omv suplementada contra meningococos
|
ATE352631T1
(de)
|
2000-02-28 |
2007-02-15 |
Novartis Vaccines & Diagnostic |
Heterologe expression von neisseria proteine
|
PT1296713E
(pt)
|
2000-06-08 |
2004-02-27 |
Intercell Biomediz Forschungs |
Oligodesoxinucleotidos imunoestimuladores
|
CZ20024224A3
(cs)
*
|
2000-06-29 |
2003-05-14 |
Glaxosmithkline Biologicals S. A. |
Farmaceutický prostředek
|
AT410635B
(de)
|
2000-10-18 |
2003-06-25 |
Cistem Biotechnologies Gmbh |
Vakzin-zusammensetzung
|
AP1897A
(en)
|
2001-01-23 |
2008-10-10 |
Aventis Pasteur |
Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
|
GB0103424D0
(en)
|
2001-02-12 |
2001-03-28 |
Chiron Spa |
Gonococcus proteins
|
WO2002079246A2
(en)
|
2001-03-30 |
2002-10-10 |
Geneprot, Inc. |
Human arginine-rich protein-related compositions
|
AU2002258734A1
(en)
|
2001-04-13 |
2002-10-28 |
Wyeth Holdings Corporation |
Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
|
EP1379272B1
(en)
|
2001-04-17 |
2010-01-20 |
Novartis Vaccines and Diagnostics, Inc. |
Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
|
JP2005508143A
(ja)
|
2001-06-07 |
2005-03-31 |
ワイス・ホールデイングス・コーポレーシヨン |
アジュバントとしてのコレラホロトキシンの突然変異形
|
CN1977971A
(zh)
|
2001-06-07 |
2007-06-13 |
惠氏控股有限公司 |
作为佐剂的霍乱全毒素的突变体形式
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
AU2002330681C1
(en)
|
2001-07-26 |
2015-04-02 |
Glaxosmithkline Biologicals S.A. |
Vaccines comprising aluminium adjuvants and histidine
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
JP2005508630A
(ja)
|
2001-09-14 |
2005-04-07 |
インヴィトロジェン コーポレーション |
Dnaポリメラーゼとその変異体
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
GB0129007D0
(en)
|
2001-12-04 |
2002-01-23 |
Chiron Spa |
Adjuvanted antigenic meningococcal compositions
|
EP1777236B8
(en)
|
2002-03-26 |
2017-02-22 |
GlaxoSmithKline Biologicals SA |
Modified saccharides having improved stability in water for use as a medicament
|
DE60328481D1
(de)
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
|
US20060147466A1
(en)
|
2002-05-14 |
2006-07-06 |
Chiron Srl |
Mucosal combination vaccines for bacterial meningitis
|
GB0302218D0
(en)
|
2003-01-30 |
2003-03-05 |
Chiron Sri |
Vaccine formulation & Mucosal delivery
|
GB0220198D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Modified saccharides,conjugates thereof and their manufacture
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
SI2353608T1
(sl)
|
2002-10-11 |
2020-12-31 |
Glaxosmithkline Biologicals Sa |
Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004065603A2
(en)
|
2003-01-15 |
2004-08-05 |
Wyeth Holdings Corporation |
Methods for increasing neisseria protein expression
|
US10272147B2
(en)
|
2003-01-30 |
2019-04-30 |
Glaxosmithkline Biologicals S.A. |
Injectable vaccines against multiple meningococcal serogroups
|
CA2519511A1
(en)
|
2003-03-17 |
2004-09-30 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
|
US20070253964A1
(en)
|
2003-04-16 |
2007-11-01 |
Zlotnick Gary W |
Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
EP2364725A3
(en)
|
2003-06-23 |
2012-05-09 |
Sanofi Pasteur Inc. |
Immunization method against neisseria meningitidis serogroups a and c
|
GB0316560D0
(en)
|
2003-07-15 |
2003-08-20 |
Chiron Srl |
Vesicle filtration
|
US8765135B2
(en)
|
2003-10-02 |
2014-07-01 |
Novartis Ag |
Liquid vaccines for multiple meningococcal serogroups
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
CN1901935A
(zh)
|
2003-12-30 |
2007-01-24 |
惠氏公司 |
具有改进耐受性的免疫原组合物中的疏水性蛋白调配物
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408977D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Immunising against meningococcal serogroup Y using proteins
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
EP1740217B1
(en)
|
2004-04-30 |
2011-06-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
ES2355980T3
(es)
|
2004-07-23 |
2011-04-01 |
Novartis Vaccines And Diagnostics S.R.L. |
Polipeptidos para ensamblaje oligomerico de antigenos.
|
GB0419408D0
(en)
|
2004-09-01 |
2004-10-06 |
Chiron Srl |
741 chimeric polypeptides
|
GB0419846D0
(en)
|
2004-09-07 |
2004-10-13 |
Chiron Srl |
Vaccine adjuvants for saccharides
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0428394D0
(en)
|
2004-12-24 |
2005-02-02 |
Chiron Srl |
Saccharide conjugate vaccines
|
SI2682126T1
(sl)
|
2005-01-27 |
2017-03-31 |
Children's Hospital & Research Center At Oakland |
Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
|
EP1855595A2
(en)
|
2005-03-07 |
2007-11-21 |
ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America |
Pharmaceutical liposomal compositions
|
PT1885734E
(pt)
|
2005-05-06 |
2015-03-04 |
Novartis Ag |
Imunogénios para vacinas contra a meningite-a
|
US8431136B2
(en)
|
2005-06-27 |
2013-04-30 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
NZ598367A
(en)
|
2005-09-01 |
2013-10-25 |
Novartis Vaccines & Diagnostic |
Multiple vaccination including serogroup C meningococcus
|
US8679770B2
(en)
|
2005-09-05 |
2014-03-25 |
Glaxo Smith Kline Biologicals S.A. |
Serum bactericidal assay for N. meningitidis specific antisera
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
AU2006327023A1
(en)
|
2005-12-23 |
2007-06-28 |
Glaxosmithkline Biologicals Sa |
Conjugate vaccines
|
NZ572054A
(en)
|
2006-03-22 |
2011-12-22 |
Novartis Ag |
Regimens for immunisation with meningococcal conjugates
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US20070253985A1
(en)
|
2006-04-26 |
2007-11-01 |
Wyeth |
Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
|
EP2032161B1
(en)
|
2006-06-12 |
2012-07-11 |
GlaxoSmithKline Biologicals S.A. |
L3v los vaccines
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
NZ573931A
(en)
|
2006-06-29 |
2012-03-30 |
Craig J Venter Inst Inc |
Polypeptides from neisseria meningitidis
|
AU2007277081B2
(en)
|
2006-07-27 |
2014-02-06 |
Wyeth Llc |
High-cell density fed-batch fermentation process for producing recombinant protein
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
MX2009013112A
(es)
|
2007-06-04 |
2010-03-01 |
Novartis Ag |
Formulacion de vacunas para meningitis.
|
US8540955B2
(en)
|
2007-07-10 |
2013-09-24 |
Wyeth Llc |
Process for producing aluminum phosphate
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2185576A4
(en)
|
2007-08-02 |
2011-01-12 |
Childrens Hosp & Res Ct Oak |
FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
|
MX340096B
(es)
|
2007-10-19 |
2016-06-27 |
Glaxosmithkline Biologicals Sa |
Formulaciones de vacuna meningococica.
|
AU2009215364B2
(en)
|
2008-02-21 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Meningococcal fHBP polypeptides
|
KR101695800B1
(ko)
|
2008-03-05 |
2017-02-22 |
사노피 파스퇴르 |
항원보강제 함유 백신 조성물의 안정화 방법
|
WO2009114485A2
(en)
|
2008-03-10 |
2009-09-17 |
Children's Hospital & Research Center At Oakland |
Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
|
US20100035234A1
(en)
|
2008-05-19 |
2010-02-11 |
Novartis Ag |
Vaccine assays
|
EP2296699A4
(en)
|
2008-05-30 |
2013-11-13 |
U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army |
POLYVALENT MENINGOCOCCULAR FUEL WITH NATIVE OUTER MEMBRANE VESICLES, METHOD OF MANUFACTURE AND USE
|
CA2734304A1
(en)
|
2008-08-27 |
2010-03-11 |
Children's Hospital & Research Center At Oakland |
Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis
|
EP2331562A4
(en)
|
2008-09-03 |
2012-07-04 |
Childrens Hosp & Res Ct Oak |
PEPTIDES WITH AN EPITOPE OF A DOMAIN OF THE FACTOR H-BINDING PROTEIN AND METHOD OF USE
|
IT1394288B1
(it)
|
2008-09-12 |
2012-06-06 |
Novartis Vaccines & Diagnostic |
Immunogeni di proteine che legano il fattore h.
|
AU2009333791B2
(en)
|
2008-10-29 |
2013-04-04 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
EP2367568A2
(en)
|
2008-12-17 |
2011-09-28 |
Novartis AG |
Meningococcal vaccines including hemoglobin receptor
|
RU2555757C2
(ru)
|
2009-03-24 |
2015-07-10 |
Новартис Аг |
Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
|
DK2411048T3
(da)
|
2009-03-24 |
2020-06-15 |
Glaxosmithkline Biologicals Sa |
Adjuvanterende meningokok-faktor h-bindingsprotein
|
WO2010127172A2
(en)
|
2009-04-30 |
2010-11-04 |
Children's Hospital & Research Center At Oakland |
Chimeric factor h binding proteins (fhbp) and methods of use
|
US9365885B2
(en)
|
2009-06-16 |
2016-06-14 |
Puiying Annie Mak |
High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
|
CN104650241A
(zh)
|
2009-08-27 |
2015-05-27 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
US20130022639A1
(en)
|
2009-09-30 |
2013-01-24 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
WO2011051893A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
E.coliキャリアタンパク質に結合体化した多糖免疫原
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
CA2792687A1
(en)
|
2010-03-10 |
2011-09-15 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
EP2547357A1
(en)
|
2010-03-18 |
2013-01-23 |
Novartis AG |
Adjuvanted vaccines for serogroup b meningococcus
|
BR112012024348B1
(pt)
|
2010-03-30 |
2022-11-08 |
Children's Hospital & Research Center At Oakland |
Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
|
WO2011161653A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
CA2808975C
(en)
|
2010-08-23 |
2018-10-30 |
Wyeth Llc |
Stable formulations of neisseria meningitidis rlp2086 antigens
|
ES2744471T3
(es)
|
2010-09-04 |
2020-02-25 |
Glaxosmithkline Biologicals Sa |
Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
|
WO2012032498A2
(en)
|
2010-09-10 |
2012-03-15 |
Novartis Ag |
Developments in meningococcal outer membrane vesicles
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
ES2864635T3
(es)
|
2010-09-10 |
2021-10-14 |
Wyeth Llc |
Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
|
US20120070457A1
(en)
|
2010-09-10 |
2012-03-22 |
J. Craig Venter Institute, Inc. |
Polypeptides from neisseria meningitidis
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
ES2681698T3
(es)
|
2011-03-02 |
2018-09-14 |
Glaxosmithkline Biologicals Sa |
Vacunas de combinación con menores dosis de antígeno y/o adyuvante
|
US9181308B2
(en)
|
2011-03-28 |
2015-11-10 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
RU2610174C2
(ru)
*
|
2011-06-24 |
2017-02-08 |
Мерк Шарп И Доум Корп. |
Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
|
EP2822583A2
(en)
|
2012-03-09 |
2015-01-14 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
JP6446377B2
(ja)
*
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
US9965924B2
(en)
|
2013-07-15 |
2018-05-08 |
Ahmnon D. Moskowitz |
Methods, systems, and apparatus for playing multi-zone 21
|
CN105492021B
(zh)
|
2013-09-08 |
2018-12-04 |
辉瑞公司 |
脑膜炎奈瑟氏球菌组合物及其方法
|
WO2016081314A1
(en)
*
|
2014-11-17 |
2016-05-26 |
Alexion Pharmaceuticals, Inc. |
Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
|
MX2017010705A
(es)
*
|
2015-02-19 |
2017-12-04 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de la misma.
|
IL303108B1
(en)
|
2017-01-31 |
2024-03-01 |
Pfizer |
NEISSERIA MENINGITIDIS preparations and methods therefor
|